PAS
KYTX icon

Point72 Asia (Singapore)’s Kyverna Therapeutics KYTX Stock Holding History

Point72 Asia (Singapore)’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$64.7K Sell
10,784
-1,255
-10% -$5.02K 0.01% 522
2025
Q2 		$37K Buy
+12,039
New +$29.8K 0.01% 649
2024
Q2 		– Sell
-10,133
Closed -$252K – 1567
2024
Q1 		$252K Buy
+10,133
New +$283K 0.07% 342

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asia (Singapore)'s KYTX Position: Q3 2025 in Review

Point72 Asia (Singapore) reduced its Kyverna Therapeutics (KYTX) stake by 10% in Q3 2025, selling an estimated $5.02K and leaving 10,784 shares worth $64.7K. The position accounts for 0.01% of the portfolio, ranked #522.

Point72 Asia (Singapore) first reported a position in KYTX in Q1 2024 and has held it in 3 quarters since. The position peaked at $252K in Q1 2024. 75 funds tracked by Wall St. Rank hold KYTX as of Q3 2025.

  • Point72 Asia (Singapore) held 10,784 shares of Kyverna Therapeutics worth $64.7K as of Q3 2025.
  • Point72 Asia (Singapore) sold 1,255 Kyverna Therapeutics shares in Q3 2025, an estimated $5.02K.
  • Kyverna Therapeutics made up 0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #522 holding.
  • Point72 Asia (Singapore) first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Point72 Asia (Singapore)'s Kyverna Therapeutics position peaked at $252K in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.